FOS and neoplasm: Targeting SF3A3 with phenylethyl isothiocyanate (PEITC) effectively suppresses tumor progression, induces apoptosis, and reduces c‐FOS expression in vitro, in vivo, and patient‐derived tumor‐like cell clusters (PTCs).